Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

2 Nov 2010
Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

1 Nov 2010
AACR announces launch of new journal, Cancer Discovery

AACR announces launch of new journal, Cancer Discovery

30 Oct 2010
PharmAthene prices registered public offering

PharmAthene prices registered public offering

29 Oct 2010
Compugen signs oncology research collaboration agreement with Seattle Genetics

Compugen signs oncology research collaboration agreement with Seattle Genetics

29 Oct 2010
Emergent BioSolutions completes Trubion acquisition

Emergent BioSolutions completes Trubion acquisition

29 Oct 2010
Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

29 Oct 2010
Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3

Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3

28 Oct 2010
GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

28 Oct 2010
Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

27 Oct 2010
Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

27 Oct 2010
Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

26 Oct 2010
Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

From Thermo Fisher Scientific Inc. 26 Oct 2010
Cancer researcher to receive 2010 AACR Award of excellence

Cancer researcher to receive 2010 AACR Award of excellence

26 Oct 2010
Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

26 Oct 2010
Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

26 Oct 2010
TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

26 Oct 2010
Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

25 Oct 2010
New report highlights numerous monoclonal antibodies for treating digestive system cancers

New report highlights numerous monoclonal antibodies for treating digestive system cancers

25 Oct 2010
Morphotek receives DOD contract to support mAb therapies against pathogenic strains

Morphotek receives DOD contract to support mAb therapies against pathogenic strains

22 Oct 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback